Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$32.91M+867.25%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Everett V. Cunningham
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 450
- Beta
- 1.04
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1.93
Financials
Revenue
$32.91M+867.3%Net Income
$-48.93MEBITDA
$-48.99MFree Cash Flow
$2.49MEPS (diluted)
$-1.04Shares Outstanding (diluted)
46.98M+2065.3%Operating Expenses
$35.17MCash & Debt
$93.53MReturn of Capital
$340.0KRevenue by Segment (annual)
$138.90MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $138.65M | $-107.15M | $-2.51 |
| 2024 | $135.44M | $-38.53M | $-1.00 |
| 2023 | $121.14M | $-28.35M | $-0.86 |
| 2022 | $105.52M | $-99.57M | $-2.61 |
| 2021 | $110.56M | $-55.55M | $-1.60 |
| 2020 | $86.38M | $-31.53M | $-1.07 |
| 2019 | $56.73M | $-40.80M | $-1.63 |
| 2018 | $37.63M | $-31.05M | $-1.41 |
| 2017 | $22.87M | $-27.02M | $-1.24 |
| 2016 | $17.59M | $-23.17M | $-1.43 |
| 2015 | $12.18M | $-15.94M | $-7.79 |
Valuation
QTRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-66.10%Social Signal Score
Mentions (6)
- Newsbusinesswire.com·19d ago·Neutral
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the “Inducement Grants”) were made to James Gute, the recently appointed Chief Commercial Officer of the Company, and two other employees in connection with the commencement of their employment. The Inducement Grant to Mr. Gute con…
View source ↗ - Newsmarketbeat.com·50d ago·Neutral
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer's Blood Test Quanterix NASDAQ: QTRX CEO Everett Cunningham said the company is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences, while acknowledging continued pressure in academic, government and biopharma markets.
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·56d ago·Negative
Quanterix Q2 Earnings Call Highlights Quanterix NASDAQ: QTRX reported second-quarter 2026 revenue of $32.9 million and lowered its full-year outlook after management cited broad-based market softness and commercial execution challenges. The company said revenue came in about $3 million, or 9%, below the guidance it provided in May.
View source ↗ - Newsbusinesswire.com·57d ago·Neutral
Quanterix Names Jim Gute Chief Commercial Officer BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that seasoned healthcare executive Jim Gute has been appointed Chief Commercial Officer of the company. In this role, he will lead a re-acceleration of growth within the company's commercial operations. “We are thrilled to attract commercial leadership of Jim's caliber to Quanterix, at a pivotal time, ahead of o
View source ↗ - Newsbusinesswire.com·57d ago·Negative
Quanterix Releases Financial Results for the Second Quarter of 2026 BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the second quarter ended June 30, 2026. “We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned. However, revenue fell short of our expectations, driven by execution challenges and continued ma
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.43 per share
Typical surprise -40.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-1.04 vs $-0.41miss
- Wed, May 6$-0.39 vs $-0.31miss
- Mon, Mar 2$-0.38 vs $-0.27miss
- Mon, Nov 10$-0.73 vs $-0.23miss
- Thu, Aug 7$-0.77 vs $-0.41miss
- Mon, May 12$-0.53 vs $-0.69beat
Estimates and results for QTRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by QTRX officers and directors.
- Bought
- $296k
- Sold
- —
3 trades
0 trades
- Donnelly William Pbought
- Donnelly William Pbought
- Meadows Benjaminbought
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in QTRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.